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Objectives. We sought to determine clinical, angiographic, and
echocardiographic predictors of survival in children with isolated
hypertrophic cardiomyopathy (HCM) in a large pediatric centre.
Background. Sudden death is a catastrophic outcome of HCM
in childhood but has been difficult to predict. Current therapies
might provide for improved outcome if factors identifying high
risk can be identified.
Methods. Records of 99 patients diagnosed with HCM from
1958 to 1997 at <18 yr were reviewed for clinical, angiographic
(n 5 62) and echocardiographic (n 5 83) predictors of survival
outcome. The effects of clinical characteristics on sudden death
(including resuscitated sudden death) were individually tested in
Cox’s proportionate hazard modeling.
Results. Seventy-one subjects were male. Median age at diag-
nosis was 5.0 yr with a medical follow-up interval of 4.8 yr.
Thirty-seven of 97 patients had a family history of HCM. Ambu-
latory electrocardiograms (ECG) in 78 patients demonstrated
supraventricular tachycardia in 16 and ventricular tachycardia in
21. Death or resuscitated sudden death occurred in 18 patients.
Sudden death rate was 2.7%/yr after age 8 yr. Cox’s proportionate
survival modeling revealed increased corrected QT interval (QTc)
dispersion on ECG (relative risk [RR] 1.61 per 20 ms increment,
p < 0.0003), ventricular tachycardia (VT) on ambulatory ECG
(RR 3.75, p < 0.006) and myocardial bridging of the LAD
coronary (RR 12.0, p < 0.003) to be associated with reduced time
to death or resuscitated sudden death.
Conclusions. Detailed assessment of ECGs, ambulatory ECGs,
and coronary angiography can assist in identifying which children
with HCM are at risk for sudden death.
(J Am Coll Cardiol 1998;32:1943–50)
©1998 by the American College of Cardiology
Hypertrophic cardiomyopathy (HCM), a heterogeneous dis-
ease of sarcomeric contractile proteins, was initially identified
in adults (1) and is thought to be uncommon in the pediatric
population (2,3). It is characterized by left-ventricular hyper-
trophy not attributable to another cause (4 – 6). Left-
ventricular hypertrophy can be manifest even shortly after
birth (7–13), or may develop in children with previously normal
echocardiographic evaluations (14).
Although the outcomes and effects of treatment have been
well characterized in adults (15–19), the pediatric literature
features smaller series (7–9,20) sometimes limited to children
with an older age at presentation (21,22). The data that does
exist on infants and young children varies with mortality rates
ranging from 0 to 50% (8,9). There is no consensus on
predictors of mortality in this population (8,9,21,22) which
makes risk stratification difficult.
To improve risk stratification in this group of patients, we
sought to describe the long-term outcomes of a large series of
infants and children with HCM and to assess possible clinical,
angiographic and echocardiographic predictors of mortality.
Methods
Patients. The cardiology database at a single tertiary pedi-
atric centre was reviewed to identify patients diagnosed with
HCM. Hypertrophic cardiomyopathy was defined by the pres-
ence of a hypertrophied, nondilated ventricle in the absence of
cardiac or systemic diseases that could produce ventricular
hypertrophy (4–6). Between 1958 and 1997, 99 patients at our
centre had been diagnosed with HCM before the age of 18
years. The initial diagnosis was confirmed by echocardiography
in 83 patients and by angiography in 16 patients diagnosed
before the availability of echocardiography.
Measurements. Medical records were reviewed to deter-
mine patients’ ages at time of presentation for medical evalu-
ation, onset of cardiovascular symptoms and diagnosis; the
presence or absence of symptoms including loss of conscious-
ness, resuscitated sudden death, presyncope, chest pain, short-
ness of breath on exertion, exercise limitation and palpitations;
and family history of HCM or sudden cardiac death. Data from
standard 12-lead electrocardiograms (ECGs), ambulatory
ECGs, exercise testing, thallium-201 scintigraphy, echocardi-
ography and cardiac catheterization were collected where
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available. The effects of both pharmacological and surgical
treatment were noted. Status at latest follow-up was recorded.
Definitions. Twelve-lead ECGs on presentation were as-
sessed for the presence of left- and right-ventricular hypertro-
phy and repolarization parameters, based on normal values
(23) and standard interpretations (24) for children. Corrected
QT interval (QTc) dispersion was calculated from a nonsimul-
taneous 12-lead ECG as the largest difference in QTc intervals
between leads (25). The end of the QT interval was defined as
the return of the repolarization trace to the isoelectric line, or
in the face of an adjoining U wave, the intersection of a tangent
to the downslope of the major repolarization wave with the
isoelectric line. Supraventricular or ventricular ectopic activity
on ambulatory ECG was defined as rare (24–240 premature
contractions per day), occasional (240–1440 premature con-
tractions/day), or frequent (.1440 premature contractions/
day).
In patients undergoing exercise testing, a Bruce treadmill
protocol (26) using standard indications for termination of
exercise was used (27). Heart rate was recorded as absolute
peak heart rate and as a percentage of the predicted value for
age. Blood pressure was recorded as absolute peak value and
as absolute change (either positive or negative) in systolic
blood pressure from the resting value; a hypotensive response
was defined as ,20 mm Hg rise in blood pressure at peak
exercise (28). Exercise duration was recorded as an absolute
value as well as a percentage of that predicted for age.
Among patients who underwent thallium-201 exercise sin-
gle photon emission tomography (SPECT) scintigraphy, a
bicycle ergometer exercise test was performed with the James
protocol (29), with exercise continued until chest pain, fatigue,
presyncope, arrhythmia or .3 mm ST segment alteration
occurred.
For echocardiography, asymmetric septal hypertrophy was
defined as a septal to posterior left-ventricular free-wall ratio
of greater than 1.5 (30). In patients receiving medical manage-
ment for obstructive disease, response to treatment was iden-
tified as no response (change in gradient ,10 mm Hg), a
transient response (reduction in gradient achieved for ,3
months) or a sustained response (reduction in gradient .3
months). Gradient reduction was noted to be mild
(10 –15 mm Hg), moderate (16 –25 mm Hg) or major
(.25 mm Hg).
Statistical analysis. Patient characteristics are expressed as
frequencies, medians with ranges, or means 61 standard
deviation, as appropriate. Group comparisons were performed
with student t test or Mann–Whitney U test as appropriate.
Where data was missing for a given variable, the number of
nonmissing values is provided. Kaplan-Meier estimates of
sudden death or resuscitated sudden death were plotted.
Patients lost to follow-up were censored at the time that they
were last known to be alive. The effect of clinical characteristics
on sudden death or resuscitated sudden death was tested with
Cox’s proportionate hazard modeling. A p value of less than
0.05 was considered significant.
Results
Between 1958 and 1997, 99 children from 93 families were
diagnosed with HCM, of which 71 were male (72%) and 28
female. Median age at diagnosis was 5.0 years (range, 1 day to
17 yr), with 30 patients diagnosed at less than 1 year of age.
Presentation and family history. Features prompting pre-
sentation included presence of a heart murmur in 41 patients,
a family history of HCM in 23 (14 other subjects with a family
history had symptoms prompting presentation), an abnormal
ECG in three and documented episode(s) of dysrhythmia in
five. Symptoms prompted presentation in 39 patients (39%).
Presenting symptoms included shortness of breath with exer-
tion in 23, chest pain in 8, resuscitated sudden death in 6,
syncope in 4 and presyncope in 1, palpitations in 4, shortness of
breath at rest in 3 and failure to thrive in 2. Of 99 patients, 70
(71%) were symptomatic at some point during follow-up.
Median age at onset of symptoms was 8.9 years (range, 0 to
18.1 yr).
Thirty-seven patients had a positive family history of HCM
in first or second degree relatives; 11 had one affected family
member; 13, two affected family members; 3, three affected
family members; and 10 had four or more family members with
HCM. Twenty-one had an associated family history of sudden
death in up to seven family members. Sixty children had no
family history of HCM. Family history was not available for
two patients.
Electrocardiography. The initial ECG was available in 93
patients and demonstrated left ventricular hypertrophy in 57
patients (61%) and right ventricular hypertrophy in 20 (22%).
Other abnormalities included prominent inferolateral Q-wave
in 59 patients, isolated ST segment changes in 36, left axis
deviation in 18, left bundle branch block in 9, right bundle
branch block in 4, left atrial enlargement in 10, right atrial
enlargement in 8, pre-excitation in 4, and right axis deviation in
7. Mean QT interval, corrected for heart rate using Bazett’s
equation (31), was 440 6 43 ms (n 5 40). Mean calculated QT
dispersion was 54 6 39 ms (n 5 78). The mean calculated QT
dispersion available for 65 surviving patients was 47.7 6 35.1
compared to 83.2 6 46.7 for 13 patients with sudden death or
resuscitated sudden death (p 5 0.0024).
Ambulatory ECGs. Ambulatory electrocardiograms
(AECGs) were performed for 78 patients and demonstrated
episodes of supraventricular tachycardia in 16 children (20%)
and ventricular tachycardia in 21 children (27%) including 9
Abbreviations and Acronyms
AECG 5 ambulatory electrocardiogram
CI 5 confidence interval
ECG 5 electrocardiogram
HCM 5 hypertrophic cardiomyopathy
QTc 5 corrected QT interval
RR 5 relative risk
VT 5 ventricular tachycardia
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with associated symptoms. Ventricular ectopy or couplets were
noted in 22 additional patients. Ischemic ST segment changes
were evident in 10 patients (13%).
Stress testing. Exercise-treadmill testing was performed in
43 patients, all without fatality. Mean exercise duration was
8.4 6 2.3 min (66 6 19% of that predicted for age). Percent-
ages of predicted heart rate averaged 90% 6 10%. Median ST
segment depression was 2 mm (range, 0 to 10 mm). Chest pain
was induced in eight patients, who had a median ST depression
of 4 mm compared to 0 mm for asymptomatic patients (p 5
0.006). Dysrhythmias included increasing ventricular ectopy in
six, ventricular tachycardia (VT) in two and second-degree
heart block in one. Mean systolic blood pressure change was
127 6 35 mm Hg, with 18 patients having a hypotensive
response to exercise. Stress thallium myocardial imaging, done
for 23 patients, showed fixed perfusion defects in 2 children,
reversible perfusion defects in 8, and no evidence of ischemia
in 13.
Echocardiography. Initial echocardiograms were available
for 83 patients. Left-ventricular hypertrophy was noted in 65
patients (78%), with 13 (16%) additional children having both
right- and left-ventricular hypertrophy, and 5 (6%) having
normal initial echocardiograms but subsequently developing
left-ventricular hypertrophy during follow-up. Mean ratio of
interventricular septum to left-ventricular free-wall thickness
was 2.3 6 1.1, with 68 patients (82%) having asymmetric septal
hypertrophy. Systolic anterior motion of the mitral valve was
noted in 58 children (70%). Right-ventricular outflow tract
obstruction was noted in 13 patients (16%), with a mean peak
instantaneous gradient of 23 6 16 mm Hg. Left-ventricular
outflow tract obstruction was noted in 49 patients (59%), with
a mean peak instantaneous gradient of 44 6 33 mm Hg.
Provocation with amyl nitrate in 27 patients resulted in an
increase in left-ventricular gradient in 11, 3 of whom had no
gradient at rest. Mitral regurgitation was qualitatively mild in
18 children, moderate in 4, and severe in 1. Mean ejection
fraction (n 5 63) was 78% 6 12%. Progressive left-ventricular
obstruction on echocardiography occurred in 43 patients
(43%) at a mean age of 9.7 6 5.4 yr.
Diastolic function was assessed in 32 patients, and the
pattern of left-ventricular diastolic filling was abnormal in 18
(56%). Mean isovolumic relaxation time was 87 6 29 ms (n 5
25); e/a ratio, 1.7 6 0.9 (n 5 26); deceleration time, 157 6
41 ms (n 5 19); and median a-wave reversal velocity, 0.18 m/s
(range, 0.0 to 0.80 m/s; n 5 23). Although diastolic abnormal-
ities in HCM may relate more directly to symptomatic status or
exercise endurance (17), they did not predict survival in our
study.
Cardiac catheterization. Cardiac catheterization was per-
formed in 62 patients. Mean left-ventricular end-diastolic
pressure (n 5 48) was 15 6 8 mm Hg. Median left-ventricular
outflow peak-to-peak gradient (n 5 61) was 10 mm Hg (range,
0 to 149). Left-ventricular systolic function was qualitatively
graded as normal in 60 patients, and significantly reduced in 2.
Median right-ventricular outflow tract peak-to-peak systolic
gradient was 0 (range, 0 to 52 mm Hg). Coronary angiography
in 36 patients showed evidence of myocardial bridging with
compression of the left anterior descending coronary artery in
ten patients.
Therapies and outcome. Sixty-four patients (65%) received
medical therapy for symptoms, outflow tract obstruction, or
arrhythmia. Forty-one patients received a b-blocking drug;
eighteen (44%) had no change in gradient despite apparent
compliance in taking a therapeutic dose. Only 10 children
(24%) experienced a sustained decrease, with a major reduc-
tion in 6 (15%). Four patients had a reduction in VT on
Table 1. Summary of Patients Dying (n 5 12)
Pt
Age
at dx
Age
at
death Symptoms
Family
mbs with
SD/HCM
QTcD
(ms)
Holter
monitor
results
LVOTO/
RVOTO
(mm Hg)
Maximum
septal
thickness
Exercise BP
response Medications Myectomy
1 2 yr 7 yr SOBOE 4 100 No data 111/23 40 mm No data None 1
2 1 wk 3 mo CHF, failure to wean
from ventilator
0 61 Normal 90/77 5 mm No data Disopyramide,
propranolol
0
3 8 yr 9 yr None 0 100 No data 0/0 50 mm No data None 0
4 1 day 4 mo SVT/CHF 0 150 VT/
SVT
0/0 6 mm No data Propranolol,
digoxin
0
5 8 yr 9 yr SOBOE 0 51 No data 20/0 15 mm No data None 0
6 10 yr 18 yr Resuscitated SD 3 88 VT 14/0 10 mm s 10 mm Hg Propranolol 0
7 10 yr 13 yr None 0 128 Normal 0/0 24 mm No change None 0
8 11 yr 14 yr SOBOE 0 79 Normal 0/0 23 mm No change None 0
9 6 yr 17 yr SOBOE, palpitations,
presyncope
0 90 VT 102/8 20 mm No change Disopyramide,
propranolol
111
10 5 yr 5 yr None 0 85 No data 0/0 20 mm No data None 0
11 11 yr 17 yr Syncope 2 100 VT 0/0 26 mm No change None 0
12 1 wk 2 yr Resuscitated SD, CHF 0 50 SVT 0/0 26 mm No change None 0
Pt 5 patient number; dx 5 diagnosis; SOBOE 5 shortness of breath on exertion; CHF 5 congestive heart failure; SVT 5 supraventricular tachycardia; SD 5
sudden death; mbs 5 members; HCM 5 hypertrophic cardiomyopathy; QTcD 5 corrected QT dispersion; VT 5 ventricular tachycardia; LVOTO/RVOTO 5
left/right-ventricular outflow tract obstruction; BP 5 blood pressure.
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AECG. Two patients with unobstructed HCM had symptom-
atic improvement, whereas three others had deteriorating
clinical symptoms that necessitated discontinuation of the
drug.
Eighteen patients were treated with disopyramide, either
primarily (n 5 10) or in addition to beta-blockade (n 5 8). Five
patients (28%) experienced no change in gradient; nine pa-
tients (50%) had a sustained reduction in gradient, which was
major in six (33%). One patient was noncompliant because of
dry mouth, a side-effect. Eight patients were treated with
calcium channel blockers (diltiazem or verapamil). A mild
sustained decrease in gradient was noted in two patients. All
patients reported an improvement in exercise-limitation symp-
toms. There were no adverse complications.
Six patients were started on amiodarone treatment for
prevention of ventricular arrhythmias. Four had clinical im-
provement and a decrease in the frequency of arrhythmia on
AECG recording and two patients had an increase in the
frequency of arrhythmia, in association with a marked increase
in the corrected QT interval. Eight patients were started on
sotalol for treatment of ventricular arrhythmias with 7 having
an improved clinical status associated with a decrease in
ventricular arrhythmia (AECG) and no change in the remain-
ing patient.
Twenty-four children underwent one or more left-
ventricular myectomies; two underwent both left- and right-
ventricular myectomies; three patients underwent isolated
right-sided myectomy. Sixteen of 29 patients (55%) had com-
plete resolution of outflow tract gradients following surgical
intervention; eight (28%) had a moderate reduction in gradi-
ent; and five patients (17%) experienced no change in gradient
following surgery. Following left-ventricular myectomy, five
patients developed complete heart block requiring permanent
pacemaker implantation. Three patients were left with greater-
than-mild aortic insufficiency; none required surgical interven-
tion. Two patients had a neurologic insult at the time of
surgery. One patient, having undergone two previous left-
ventricular myectomies, died in the immediate post-operative
period.
Six children had insertion of an implantable cardioverter
defibrillator because of resuscitated sudden death with two of
these patients also undergoing unroofing of a myocardial
bridge because of evidence of ischemia-induced ventricular
dysrhythmias. One underwent unroofing of a myocardial
bridge during a separate procedure because of recurrent
defibrillator discharges into what appeared to be ischemia-
induced ventricular tachycardia. An additional patient had
isolated unroofing of a myocardial bridge. One patient under-
went cryoablation of an accessory pathway, with concomitant
pacemaker implantation, for intractable supraventricular
tachycardia. Two patients went on to cardiac transplantation
after developing end-stage heart failure.
Characteristics of the 12 patients who died are listed in
Table 1. Two of these patients had a previous resuscitated
sudden death. An additional six patients experienced resusci-
tated sudden death but continue to survive. Patients were
followed up to their last clinic visit at 18 yr or until death. Two
patients were lost to follow-up. The remainder were followed
to a mean age of 12.1 6 6.3 years, for a median interval from
diagnosis of 4.8 years. Kaplan–Meier estimates of freedom
from death or resuscitated sudden death are graphed, from
birth in Figure 1 and from time of diagnosis in Figure 2. The
yearly combined incidence of death or resuscitated sudden
death between 8 and 18 years of age has been constant at 2.7%
per yr.
When variables (Table 2) were tested individually with
Cox’s proportionate hazard modeling to determine their effect
on time from diagnosis to death or to resuscitated sudden
death, those significantly associated with an increased risk
included increased QT dispersion on baseline ECG (relative
risk [RR], 1.61 per 20 ms incremental increase; 95% confi-
dence interval [CI], 1.24 to 2.08), presence of ventricular
tachycardia on ambulatory monitoring (RR 3.75, CI 1.48 to
9.50), and the presence of myocardial bridging on coronary
angiography (RR 12.0, CI 2.47 to 58.3). The presence of ST
segment depression on exercise testing approached but did not
reach significance. History of symptoms, age at diagnosis,
Figure 1. Kaplan-Meier life-table analysis of freedom from death or
resuscitated sudden death vs patient age. Dashed lines indicate 62
standard deviations.
Figure 2. Kaplan-Meier life-table analysis of freedom from death or
resuscitated sudden death vs length of time since diagnosis. Dashed
lines indicate 62 standard deviations.
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positive family history of HCM or HCM-associated sudden
death, ECG voltage criteria for hypertrophy, left-ventricular
outflow tract obstruction, diastolic dysfunction and treatment
with medication or surgery did not correlate with an increased
risk of mortality (Table 2).
Discussion
The clinical course of HCM in children is variable; asymp-
tomatic or mildly symptomatic patients may die unexpectedly
(5,32,33). Although it has been postulated that the best
determinant of outcome may be the specific molecular genetic
defect (6), current patient management relies on clinical
predictors of outcome. Although literature on outcome deter-
minants in adults is ample, data on risk factors for mortality in
children is sparse, and that which is available is controversial.
In previous studies, increased risk of mortality in children with
HCM has been associated with a history of syncope on
presentation (21,34), the presence of congestive heart failure
in the first year of life (9), malignant family history (35),
high-grade ventricular ectopy on ambulatory recording (19)
and evidence of ischemia on noninvasive testing (36). In
contrast, we found that only the last two of these factors were
predictive of death or resuscitated sudden death in our pa-
tients, plus two others (presence of increased QTc dispersion
and myocardial bridging). The explanations for our contrasting
findings may be related to methodology, statistical power,
differences in practice or patient population.
Comparison of our study to that of McKenna and Deanfield
(21) demonstrates differing methodology and practice. They
found a history of syncope to be a risk factor for sudden death
with four of four patients who presented with loss of conscious-
ness subsequently experiencing sudden death. In contrast,
within our population there was no association between a
history of loss of consciousness and sudden death. We defined
syncope as a brief loss of consciousness requiring no resusci-
tative efforts and analyzed these patients separately from those
who presented with resuscitated sudden death, whereas
McKenna and Deanfield (21) did not distinguish between
these two forms of consciousness loss. None of their patients
received a defibrillator, while six of our eight patients with
resuscitated sudden death had implantation of an internal
defibrillator. Many were also treated with a class III antiar-
rhythmic and/or unroofing of a myocardial bridge. Most of the
patients with a defibrillator subsequently experienced appro-
priate discharge, suggesting that such treatment was, in fact,
protective. The remaining two patients not implanted with a
defibrillator died suddenly. It would appear that while a history
of syncope may not confer an increased risk of mortality, a
history of resuscitated sudden death does.
In contrast to the multi-institutional NIH study of Maron
and colleagues, 21 of our 23 patients diagnosed under the age
of one yr survived. This may be due to improvements in
therapies for these infants which have occurred since this
earlier study.
The frequency of a positive family history of HCM in our
patients was 38%, somewhat less than that found by Greaves et
al. (37). However, many of the patients may have been
investigated when family screening was not routinely per-
formed. While 22% of our patients had a positive family
history of HCM associated with sudden death, such a history
was not predictive of childhood mortality. Previous studies
have found an association between a malignant family history
and sudden death (35,38,39). The lack of such an association
within our patient population may reflect a follow-up duration
confined to the childhood and adolescent years or an aggres-
sive treatment approach in those with a family history of
sudden death (40).
Frenneaux et al. (41) previously reported an increased risk
of resuscitated sudden death in adult patients with HCM who
had documented exercise-induced hypotension. The six pa-
tients in this study series who had undergone formal exercise
testing and then died suddenly had, in concordance with the
findings of others, failed to elevate their blood pressure with
exercise (Table 1), but this did not reach statistical significance.
ST segment depression on exercise approached statistical
significance as a predictor of sudden death, supporting a
similarly reported association between ischemia (on exercise
thallium study) and sudden death (36).
Ventricular dysrhythmias have long been postulated as the
mechanism of sudden death in children with HCM (16,19,42).
We documented a high incidence of sudden death in those
patients with ventricular tachycardia on ambulatory recording.
This is in keeping with the findings of two previous indepen-
dent studies associating nonsustained VT with sudden cardiac
Table 2. Postulated Risk Factors for Reduced Time to Death or
Resuscitated Sudden Death
Variable Relative risk p value n
Presence of symptoms 1.45 0.46 99
Syncope 0.33 0.29 99
Chest pain 0.77 0.65 99
Age at diagnosis (per 1 yr
increment)
1.06 0.23 99
Family history of HCM 1.34 0.54 99
Family history of sudden death 1.86 0.22 99
Interventricular septal thickness
(per mm inc.)
1.03 0.11 80
Left-ventricular outflow
gradient $20 mm Hg
0.92 0.22 98
Medication 1.63 0.36 99
Surgery 1.78 0.23 99
ST segment depression on
exercise test
2.45 0.06 99
QTc dispersion (per 20 ms
increment)
1.61 *0.0003 78
Ventricular tachycardia on
ambulatory ECG
3.75 *0.006 99
Myocardial bridging of LAD
coronary artery
12.0 *0.003 36
*Statistically significant. HCM 5 hypertrophic cardiomyopathy; inc. 5
increment; QTc 5 corrected QT interval; ECG 5 electrocardiogram; LAD 5
left anterior descending.
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death (43,44). Spirito (45) in a selected population of asymp-
tomatic patients, assessed only the initial AECG and found
that the presence of nonsustained VT did not reach signifi-
cance as a predictor of mortality, although the RR was 2.4.
Interlead QT variability on surface ECG, defined as QT
dispersion, is thought to reflect regional variations in myocar-
dial recovery (46–48). Adults with HCM have been shown to
have a greater degree of QT dispersion than normal (49), and
those with HCM experiencing sudden death have been noted
to have greater QT dispersion than other adult HCM patients
(25). We recently documented increased QT dispersion in a
subgroup of children with HCM and systolic compression of
the left anterior descending coronary artery on coronary
angiography, compared to those without evidence of coronary
compression (50). In our present study population, greater QT
dispersion on ECG was strongly associated with an increased
risk of mortality. The etiology of this increase in QT dispersion
has not been well defined, but may relate to ischemia-induced
alteration in myocardial repolarization (51).
Additional evidence supporting the role of regional myo-
cardial ischemia in sudden death in children with HCM has
included increasing myocardial lactate production with rapid
atrial pacing (52), appearance of reversible exercise-induced
perfusion defects on thallium scanning (36) and transmural
infarcts on autopsy (53). We have shown an association
between increased risk of mortality and ischemic ECG changes
on exercise testing which approaches statistical significance.
Few patients underwent thallium scanning, and we were
unable to demonstrate an association between reversible per-
fusion defects with exercise and subsequent mortality. The
mechanism of ischemia remains undefined, but proposed
factors include intramural small-vessel abnormalities (6,15,32),
septal perforator artery compression (6,15,32), abnormal myo-
cellular architecture (6), massive hypertrophy (54), or myocar-
dial bridging with systolic compression of the left anterior
descending coronary artery (50,55).
Management. The role of b-blockers in the treatment of
children with HCM is controversial (8,9,18,22,56,57).
b-blocking drugs have been shown to improve exertional
angina and dyspnea in patients with HCM by inhibiting
sympathetic stimulation of the heart and diminishing myocar-
dial oxygen requirements (15). b-blockers are thought to
improve diastolic function through a reduction in heart rate
and a reduction in myocardial ischemia (15,36). Relief of
outflow tract obstruction by blocking sympathetic tone is also
thought to lead to an improvement in symptoms. Within our
patient population, the effect of beta-blockade on left-
ventricular outflow tract obstruction was inconsistent.
The role of disopyramide in pediatric patients with HCM
and left-ventricular outflow tract obstruction has only been
assessed in a small series (58). The drug is thought to be
potentially useful in reducing subaortic obstruction secondary
to its negative inotropic effect. We report the successful
sustained relief of left-ventricular outflow tract obstruction in
half of the children treated. Disopyramide may also have an
antiarrhythmic effect when administered to patients, although
we have not deliberately used it for this indication.
Calcium channel blockers have previously been shown to be
effective agents in the management of children with HCM
(20,59,60), improving cardiac symptoms and exercise capacity
in most HCM patients, regardless of whether obstruction is
present (15,20). Mechanisms thought to underlie this benefi-
cial effect include a mild negative inotropic effect (15) and an
improvement in diastolic function (15,59).
Amiodarone and sotalol may assume increasing importance
as therapeutic agents in children with HCM and documented
VT. Both drugs have been shown to reduce QT dispersion
(49,61) and to protect against malignant ventricular dysrhyth-
mias in this group of patients. Six of eight patients experiencing
resuscitated sudden death in our series had implantation of an
automatic defibrillator. All patients are alive at follow-up. In
addition to a history of resuscitated sudden death, other
indications for defibrillator implantation may include symp-
tomatic ventricular tachycardia uncontrolled by medical or
surgical management. We have not had a patient receiving
either drug experience sudden death.
When medical management is ineffective or not tolerated in
symptomatic children with obstructive cardiomyopathy, surgi-
cal myectomy should be undertaken. A persistent left-
ventricular outflow tract gradient .60 mm Hg despite medi-
cation is also suggested as an indication for surgery, regardless
of symptomatology (62). Surgical complications in our series
included aortic insufficiency, complete heart block, and neuro-
logic sequelae (63).
Surgical unroofing of a myocardial bridge in the setting of
angiographically documented coronary compression may
prove valuable in reducing ischemia (64). All patients with a
myocardial bridge who did not undergo surgical unroofing had
evidence of ongoing ischemia and repeat episodes of resusci-
tated sudden death or death. There was no evidence of
ischemia on exercise testing or perfusion scanning in those
undergoing surgical relief of the obstruction, as well as no
recurrence of resuscitated sudden death (50).
Recommendations. All patients with evidence for isch-
emia, based on clinical history or laboratory findings such as
chest pain, resting or exercise-induced ST segment changes,
excessive QT dispersion or ventricular dysrhythmias should be
evaluated with nuclear exercise testing and coronary angiogra-
phy to rule out septal perforator artery compression or myo-
cardial bridging with systolic compression of the left anterior
descending artery (50). Patients with documented ischemia
from myocardial bridging should undergo coronary unroofing,
in addition to implantation of an automatic implantable car-
dioverter defibrillator if there is a history of resuscitated
sudden death. Patients with evidence of ischemia, but no
surgically correctable lesion, may benefit from medical man-
agement with b-blockers or calcium-channel blockers (6,50).
All patients with loss of consciousness should be evaluated
as to other potential manifestations of ischemia (angina or
exercise-induced syncope) and undergo Holter ambulatory
monitoring, echocardiographic evaluation of systolic and dia-
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stolic function, measurement of left-ventricular outflow tract
gradient at rest and with provocation, cardiac catheterization
with coronary angiography to evaluate for the presence of
myocardial bridging (50) and radionuclide exercise testing to
assess for the presence of ischemia or ischemia-induced ar-
rhythmias. Dispersion of refractoriness should be specifically
assessed on ECG.
Limitations. Although this is one of the largest reported
series of children with hypertrophic cardiomyopathy, it is also
therefore retrospective over a long period of evolving practice.
The development of surgical excellence in relief of outflow
tract obstruction may have led to some referral bias, although
probably not to the extent of other large series. The presence
of a stable coding system and clinical database throughout the
period of study provided for the study of all cases and their
investigations, although no consistent investigative strategy was
maintained throughout this period. Only selected investiga-
tions were performed in each patient. Therefore, predictors
could only be assessed independently, and their interrelation-
ships could not be explored in multivariate analysis.
Interpretation. Mortality in this large series of children
with HCM is lower than that previously reported. Sudden
death continues to be the primary cause of death in these
patients. Evidence is increasing that the underlying cause of
sudden death is myocardial ischemia, often secondary to
myocardial bridging. Ventricular tachycardia, increased QT
dispersion, and ST segment changes on exercise testing appear
to be markers of an increased risk of mortality and may all
reflect ongoing ischemia. An aggressive diagnostic evaluation
to detect ischemia and the use of a multifaceted treatment
approach to prevent ischemia may be beneficial.
We sincerely acknowledge the assistance of Editorial Services, The Hospital for
Sick Children, Toronto, Ontario, Canada.
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